Trial Profile
Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib PCR-Monitoring, Adherence, Quality of Life, Therapy Satisfaction
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Biomarker; Therapeutic Use
- Acronyms DasPAQT
- 24 Jul 2019 Status changed from active, no longer recruiting to completed.
- 11 Mar 2019 Planned End Date changed from 1 Apr 2019 to 1 May 2019.
- 11 Mar 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Mar 2019.